AU2023206363A1 - Vegf and tie2-binding fusion protein and uses thereof - Google Patents

Vegf and tie2-binding fusion protein and uses thereof Download PDF

Info

Publication number
AU2023206363A1
AU2023206363A1 AU2023206363A AU2023206363A AU2023206363A1 AU 2023206363 A1 AU2023206363 A1 AU 2023206363A1 AU 2023206363 A AU2023206363 A AU 2023206363A AU 2023206363 A AU2023206363 A AU 2023206363A AU 2023206363 A1 AU2023206363 A1 AU 2023206363A1
Authority
AU
Australia
Prior art keywords
fusion protein
identity
seq
vegf
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023206363A
Other languages
English (en)
Inventor
Minkyung CHOO
Philip DUROST
Sangyeul HAN
Kwangsoo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ingenia Therapeutics Inc
Original Assignee
Ingenia Therapeutics Inc
Ingenia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenia Therapeutics Inc, Ingenia Therapeutics Inc filed Critical Ingenia Therapeutics Inc
Publication of AU2023206363A1 publication Critical patent/AU2023206363A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023206363A 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof Pending AU2023206363A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263299177P 2022-01-13 2022-01-13
US63/299,177 2022-01-13
US202263310359P 2022-02-15 2022-02-15
US63/310,359 2022-02-15
US202263335805P 2022-04-28 2022-04-28
US63/335,805 2022-04-28
PCT/US2023/060582 WO2023137395A1 (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Publications (1)

Publication Number Publication Date
AU2023206363A1 true AU2023206363A1 (en) 2024-08-15

Family

ID=87279731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023206363A Pending AU2023206363A1 (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Country Status (16)

Country Link
US (1) US20230287109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4463482A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884072B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250005053A (cg-RX-API-DMAC7.html)
AU (1) AU2023206363A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242904A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024002106A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010934A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240342A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000136A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416581A (cg-RX-API-DMAC7.html)
IL (1) IL314219A (cg-RX-API-DMAC7.html)
JO (1) JOP20240158A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008737A (cg-RX-API-DMAC7.html)
PE (1) PE20260003A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023137395A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
WO2026036282A1 (en) * 2024-08-13 2026-02-19 Pentavision Biosciences Limited Multispecific fusion proteins targeting angiogenic factors
US20260226178A1 (en) * 2024-12-23 2026-08-06 Ingenia Therapeutics, Inc. Fusion Proteins Comprising a Tie2 Binding Domain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415533A1 (en) * 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies uses thereof
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
JP2021507723A (ja) * 2017-12-05 2021-02-25 ユニバーシティ オブ ワシントンUniversity of Washington 視細胞における治療遺伝子の機能的発現を増強するための組成物および方法
WO2019235856A1 (ko) * 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
EP3805265A4 (en) * 2018-06-07 2022-07-06 Institute for Basic Science ANTIBODIES BINDING TO TIE2 AND USES THEREOF
JP2021529557A (ja) * 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
JP7249060B2 (ja) * 2018-08-17 2023-03-30 トリカン・バイオテクノロジー・カンパニー・リミテッド 抗血管新生融合タンパク質およびその使用
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
AU2020385991A1 (en) * 2019-11-21 2022-06-23 Unity Biotechnology Antibodies directed to Tie-2 and methods of use
CA3169967A1 (en) * 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use

Also Published As

Publication number Publication date
IL314219A (en) 2024-09-01
KR20250005053A (ko) 2025-01-09
GEAP202416581A (en) 2024-12-10
JP7884072B2 (ja) 2026-07-02
WO2023137395A1 (en) 2023-07-20
DOP2024000136A (es) 2024-10-15
CL2025002473A1 (es) 2025-11-14
MX2024008737A (es) 2024-09-11
US20230287109A1 (en) 2023-09-14
JOP20240158A1 (ar) 2024-07-14
CA3242904A1 (en) 2025-03-14
JP2025503704A (ja) 2025-02-04
EP4463482A1 (en) 2024-11-20
CL2024002106A1 (es) 2025-03-28
EP4463482A4 (en) 2026-05-06
CR20240342A (es) 2024-09-18
PE20260003A1 (es) 2026-01-06
CO2024010934A2 (es) 2024-10-31

Similar Documents

Publication Publication Date Title
JP7314356B2 (ja) 改変j鎖を有する結合分子
US20230287109A1 (en) VEGF and TIE2-Binding Fusion Protein and Uses Thereof
US20210040181A1 (en) Targeted therapeutics based on engineered proteins that bind egfr
US20250051413A1 (en) Chimeric molecules comprising il-12 agonist polypeptide
US11498962B2 (en) Anti-angiopoietin-2 antibodies that induce Tie2 activation
KR102455680B1 (ko) 신규 항인간 Tie2 항체
EP3646887A1 (en) Conjugate of vegf-grab protein and drug, and use thereof
US20160024483A1 (en) Method of treating eye disease using glycosylated vegf decoy receptor fusion protein
JP7700189B2 (ja) 抗Tie2抗体およびその使用
CN115925977B (zh) 双特异性融合多肽及其应用
JP2025523049A (ja) 抗Nectin-4抗体及びその使用
JP2025508317A (ja) 抗cd3及び抗cd20二重特異性抗体、並びにその使用
EP4559932A1 (en) Multispecific antibody and use thereof
CN117529494A (zh) 包括il-12激动剂多肽的嵌合分子
CN114656567A (zh) 抗icos抗体及其应用
KR20140025836A (ko) 항 HER2/Neu 단일클론항체와 IL-7가 연결된 융합 단일클론 항체 및 이를 포함하는 암 치료용 조성물
HK40118737A (en) Vegf and tie2-binding fusion protein and uses thereof
CN118922443A (zh) 结合VEGF和Tie2的融合蛋白及其用途
WO2025070337A1 (ja) 抗MerTKアゴニスト抗体、抗MerTK二重特異性抗体、及びその使用
HK40130178A (en) Antibody binding to tie2 and use thereof
WO2025140497A1 (zh) Pvrig结合蛋白、双特异性抗体及其应用
CN119219777A (zh) 4-1bb结合蛋白
CN121064327A (zh) Gipr、glp1r和/或gcgr的调节剂及其用途